scholarly journals Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B

2000 ◽  
Vol 46 (3) ◽  
pp. 475-477 ◽  
Author(s):  
M. Cuenca-Estrella
Keyword(s):  
Amphotericin B ◽  
Clinical Isolates ◽  
Candida Spp ◽  
Fluconazole Resistant

scholarly journals In Vitro Activities of Fluconazole and Voriconazole against Clinical Isolates of Candida spp. Determined by Disk Diffusion Testing in Turin, Italy

2009 ◽  
Vol 53 (4) ◽  
pp. 1657-1659 ◽  
Author(s):  
Narcisa Mandras ◽  
Vivian Tullio ◽  
Valeria Allizond ◽  
Daniela Scalas ◽  
Giuliana Banche ◽  
...  
Keyword(s):  
Clinical Isolates ◽  
Disk Diffusion ◽  
In Vitro Activity ◽  
High Susceptibility ◽  
Diffusion Test ◽  
Candida Spp ◽  
Disk Diffusion Test ◽  
Disk Diffusion Testing ◽  
Fluconazole Resistant

ABSTRACT The in vitro activities of fluconazole and voriconazole against 1,024 clinical isolates of Candida spp. were determined by the agar disk diffusion test using the Clinical and Laboratory Standards Institute (CLSI) M44-A guidelines. The results of this investigation demonstrated the broad-spectrum in vitro activity of voriconazole, relative to that of fluconazole, against yeasts tested, in particular fluconazole-resistant isolates, such as Candida krusei that showed high susceptibility to voriconazole. The situation in Turin, Italy, is quite similar to that of the rest of Italy, reflecting the worldwide trend.

scholarly journals Activities of Micafungin against 315 Invasive Clinical Isolates of Fluconazole-Resistant Candida spp.

2006 ◽  
Vol 44 (2) ◽  
pp. 324-326 ◽  
Author(s):  
S. A. Messer ◽  
D. J. Diekema ◽  
L. Boyken ◽  
S. Tendolkar ◽  
R. J. Hollis ◽  
...  
Keyword(s):  
Clinical Isolates ◽  
Candida Spp ◽  
Fluconazole Resistant

scholarly journals Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae.

1997 ◽  
Vol 41 (2) ◽  
pp. 233-235 ◽  
Author(s):  
M A Pfaller ◽  
S Messer ◽  
R N Jones
Keyword(s):  
Saccharomyces Cerevisiae ◽  
Antifungal Activity ◽  
Amphotericin B ◽  
Clinical Laboratory ◽  
Clinical Isolates ◽  
National Committee ◽  
Candida Spp ◽  
In Vitro Susceptibility ◽  
Broth Microdilution Method

Sch 56592 is a new triazole agent with potent, broad-spectrum antifungal activity. The in vitro activities of Sch 56592, itraconazole, fluconazole, amphotericin B, and flucytosine (5-FC) against 404 clinical isolates of Candida spp. (382 isolates) and Saccharomyces cerevisiae (22 isolates) were investigated. In vitro susceptibility testing was performed by a broth microdilution method performed according to National Committee for Clinical Laboratory Standards guidelines. Overall, Sch 56592 was very active (MIC at which 90% of isolates are inhibited [MIC90], 0.5 microgram/ml) against these yeast isolates. Sch 56592 was most active against Candida tropicalis, Candida parapsilosis, candida lusitaniae, and Candida stellatoidea (MIC90, < or = 0.12 microgram/ml) and was least active against Candida glabrata (MIC90, 2.0 micrograms/ml). Sch 56592 was 2- to 32-fold more active than amphotericin B and 5-FC against all species except C. glabrata. By comparison with the other triazoles, Sch 56592 was equivalent to itraconazole and greater than or equal to eightfold more active than fluconazole. On the basis of these results, Sch 56592 has promising antifungal activity, and further in vitro and in vivo investigations are warranted.

scholarly journals Distribution and susceptibility to amphotericin B and fluconazole of Candida spp. isolated from Taiwan

2005 ◽  
Vol 133 (2) ◽  
pp. 325-330 ◽  
Author(s):  
Y. L. YANG ◽  
Y. A. HO ◽  
H. H. CHENG ◽  
H. J. LO
Keyword(s):  
Drug Resistance ◽  
Amphotericin B ◽  
High Resistance ◽  
Positive Association ◽  
Resistance Rate ◽  
Candida Spp ◽  
Yeast Strains ◽  
Fluconazole Resistant

Susceptibilities to amphotericin B and fluconazole of 628 clinical yeast strains collected from 22 hospitals in Taiwan were determined. A total of 53 isolates (8·4%) were resistant to fluconazole. Each hospital had different resistance rate to fluconazole ranging from 0% to 24%. None of the 186 isolates from eight of the 22 hospitals was resistant to fluconazole. In contrast, isolates from nine of the remaining 14 hospitals had greater than 10% resistance rate to fluconazole. Consistently, 88·9% (8/9) fluconazole-resistant C. albicans isolates were from hospitals having a high resistance rate to fluconazole. The prevalence of various Candida spp. in each hospital was different. A positive association was found between the prevalence of C. tropicalis and the resistance rate to fluconazole for individual hospitals. Although only three isolates (0·5%) were resistant to amphotericin B, a co-resistance to both amphotericin B and fluconazole was observed, which highlights the emerging problem of drug resistance.

scholarly journals In Vitro Activities of Ravuconazole and Voriconazole Compared with Those of Four Approved Systemic Antifungal Agents against 6,970 Clinical Isolates of Candida spp

2002 ◽  
Vol 46 (6) ◽  
pp. 1723-1727 ◽  
Author(s):  
M. A. Pfaller ◽  
S. A. Messer ◽  
R. J. Hollis ◽  
R. N. Jones ◽  
D. J. Diekema
Keyword(s):  
Candida Albicans ◽  
Amphotericin B ◽  
Antifungal Agents ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Candida Spp ◽  
Medical Centers ◽  
Dose Dependent

ABSTRACT The in vitro activities of ravuconazole and voriconazole were compared with those of amphotericin B, flucytosine (5FC), itraconazole, and fluconazole against 6,970 isolates of Candida spp. obtained from over 200 medical centers worldwide. Both ravuconazole and voriconazole were very active against all Candida spp. (MIC at which 90% of the isolates tested are inhibited [MIC90], 0.25 μg/ml; 98% of MICs were ≤1 μg/ml); however, a decrease in the activities of both of these agents was noted among isolates that were susceptible-dose dependent (fluconazole MIC, 16 to 32 μg/ml) and resistant (MIC, ≥ 64 μg/ml) to fluconazole. Candida albicans was the most susceptible species (MIC90 of both ravuconazole and voriconazole, 0.03 μg/ml), and C. glabrata was the least susceptible species (MIC90, 1 to 2 μg/ml). Ravuconazole and voriconazole were each more active in vitro than amphotericin B, 5FC, itraconazole, and fluconazole against all Candida spp. and were the only agents with good in vitro activity against C. krusei. These results provide further evidence for the spectrum and potency of ravuconazole and voriconazole against a large and geographically diverse collection of Candida spp.

Antifungal Resistance Trends of Candida auris Clinical Isolates, New York-New Jersey, 2016-2020

2022 ◽  
Author(s):  
Shannon Kilburn ◽  
Gabriel Innes ◽  
Monica Quinn ◽  
Karen Southwick ◽  
Belinda Ostrowsky ◽  
...  
Keyword(s):  
New York ◽  
New Jersey ◽  
Amphotericin B ◽  
Regional Differences ◽  
Antifungal Resistance ◽  
Clinical Isolates ◽  
Candida Auris ◽  
Fluconazole Resistant ◽  
Echinocandin Resistance ◽  
Clinical Cases

About 55% of U.S. Candida auris clinical cases were reported from New York and New Jersey from 2016 through 2020. Nearly all New York-New Jersey clinical isolates (99.8%) were fluconazole resistant, and 50% were amphotericin B resistant. Echinocandin resistance increased from 0% to 4% and pan-resistance increased from 0 to <1% for New York C. auris clinical isolates but not for New Jersey, highlighting the regional differences.

Sign in / Sign up

Export Citation Format

Share Document